Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.

Abstract:

:Actinic keratosis (AK) and basal cell carcinoma (BCC) are precancerous and cancerous skin lesions that should be treated especially when multiple or in cosmetically important areas. Apart from 5% 5-fluorouracil topical cream, which some feel is the gold standard topical treatment for AK, several invasive treatment modalities are available for AK and superficial BCC, such as cryotherapy, electrodessication, carbon dioxide laser and surgery causing patients discomfort and pain, pigmentary changes or necessitate multiple office visits. Additionally, there are precancerous lesions that necessitate non-invasive treatment with good esthetic results or skin cancer refractory to invasive techniques. Imiquimod is an immune response modifier approved by the FDA for the treatment of AK and superficial BCC lesions and its use is gradually expanded to various off-label precancerous and cancerous skin lesions.

authors

Papadavid E,Stratigos AJ,Falagas ME

doi

10.1517/14656566.8.11.1743

subject

Has Abstract

pub_date

2007-08-01 00:00:00

pages

1743-55

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

8

pub_type

杂志文章,评审
  • Dapagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.812632

    authors: Abdul-Ghani MA,DeFronzo RA

    更新日期:2013-08-01 00:00:00

  • Amifostine: chemotherapeutic and radiotherapeutic protective effects.

    abstract::Amifostine (Ethyoltrade mark, Alza Pharmaceuticals) is an inorganic thiophosphate cytoprotective agent known chemically as ethanethiol, 2-[3- aminopropyl)amino]dihydrogen phosphate. It is a prodrug of free thiol (WR-1065) that may act as a scavenger of free radicals generated in tissues exposed to cytotoxic drugs and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.3.479

    authors: Santini V

    更新日期:2001-03-01 00:00:00

  • Itraconazole.

    abstract::Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.2.287

    authors: Piérard GE,Arrese JE,Piérard-Franchimont C

    更新日期:2000-01-01 00:00:00

  • Sorafenib: a clinical and pharmacologic review.

    abstract:IMPORTANCE OF THE FIELD:Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases (vascular endothelial growth factor receptors 1, 2, 3 and platelet-derived growth factor-beta, Flt-3 and c-kit) that are implicated in tumorigenesis and tumor progress...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.496453

    authors: Iyer R,Fetterly G,Lugade A,Thanavala Y

    更新日期:2010-08-01 00:00:00

  • Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

    abstract:INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.854771

    authors: Yamaoka K,Tanaka Y

    更新日期:2014-01-01 00:00:00

  • Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

    abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1526923

    authors: Moore BR,Davis TME

    更新日期:2018-11-01 00:00:00

  • Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.

    abstract::Maximal surgical debulking and radiotherapy have been the cornerstone of therapy for high-grade gliomas. The impact of chemotherapy on outcome has been marginal and, until recently, its usage has been debatable. The development of new drugs and an improved understanding of chemoresistance have reinvigorated interest i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.6.749

    authors: Cavaliere R,Newton H

    更新日期:2006-04-01 00:00:00

  • Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

    abstract:INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557359

    authors: Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

    更新日期:2011-03-01 00:00:00

  • Varicella zoster: an update on current treatment options and future perspectives.

    abstract:INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.860443

    authors: Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

    更新日期:2014-01-01 00:00:00

  • The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction.

    abstract:OBJECTIVE:To investigate the impact of daily sildenafil on levels of soluble molecular markers of endothelial function in men with erectile dysfunction. METHODS:Patients aged >18 years with erectile dysfunction of vascular etiology for >6 months, either alone or in combination with disease states strongly associated w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560802678211

    authors: Konstantinopoulos A,Giannitsas K,Athanasopoulos A,Spathas D,Perimenis P

    更新日期:2009-02-01 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1149164

    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • Treatment of dyslipidaemia in HIV-infected persons.

    abstract::Accumulating evidence suggests that HIV-infected individuals have an increased risk of cardiovascular events. This risk seems to be at least partially mediated by dyslipidaemia, which is related to the use of highly active antiretroviral therapy (HAART). As HIV-infected individuals live longer due to HAART, their card...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.10.1619

    authors: Manuel O,Thiébaut R,Darioli R,Tarr PE

    更新日期:2005-08-01 00:00:00

  • Moxonidine: some controversy.

    abstract::Initially it was considered that moxonidine, like clonidine, acted at central (2)-adrenoceptors to reduce blood pressure. With the characterisation of imidazoline binding sites distinct from (2)-adrenoceptors, the consensus became that moxonidine was acting predominantly at imidazoline I(1) receptors in the rostral ve...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.2.337

    authors: Doggrell SA

    更新日期:2001-02-01 00:00:00

  • Current trends in antithyroid drug treatment of Graves' disease.

    abstract:INTRODUCTION:Graves' hyperthyroidism is associated with significant morbidity and mortality risk. The thionamides, methimazole, its pro-drug derivative carbimazole, and propylthiouracil, remain a cornerstone of management. Yet despite decades of use, optimal strategies for maximising treatment response and curtailing a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1232388

    authors: Okosieme OE,Lazarus JH

    更新日期:2016-10-01 00:00:00

  • Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.

    abstract::Introduction: Influenza represents a major public health threat worldwide. Implementation of good personal health and hygiene habits, together with vaccination, is the most effective tools to reduce influenza burden both in community and in healthcare setting. However, achieving adequate vaccination rates is challengi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1626824

    authors: Bassetti M,Castaldo N,Carnelutti A

    更新日期:2019-10-01 00:00:00

  • Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

    abstract:INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.651127

    authors: Guarneri V,Dieci MV,Conte P

    更新日期:2012-02-01 00:00:00

  • Current and future therapies for the treatment of histamine-induced angioedema.

    abstract:INTRODUCTION:Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1282461

    authors: James C,Bernstein JA

    更新日期:2017-02-01 00:00:00

  • Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.

    abstract:INTRODUCTION:Chronic obstructive pulmonary disease (COPD) is a complex respiratory disorder, whose medical and socioeconomic burden as one of the main causes of morbidity and mortality is increasing worldwide. COPD pathophysiology includes chronic airway/lung inflammation and progressive airflow limitation. Therefore, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1070826

    authors: Pelaia G,Muzzio CC,Vatrella A,Maselli R,Magnoni MS,Rizzi A

    更新日期:2015-01-01 00:00:00

  • Child cured of HIV: can this be repeated?

    abstract::Eradication of HIV infection is the most challenging research area in the HIV/AIDS field. Treatment of HIV infection with antiretrovirals halts viral replication but fails to eradicate infection because it does not eliminate latent viruses. Eradication has only been achieved in one exceptional case after bone marrow t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2013.835396

    authors: Blanco J

    更新日期:2013-12-01 00:00:00

  • Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.

    abstract::Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.2065

    authors: Halbreich U,Kahn LS

    更新日期:2003-11-01 00:00:00

  • Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

    abstract:OBJECTIVE:The intent of this pooled analysis was to determine the relationship between baseline depression symptom severity and treatment response for escitalopram compared to that for other pooled antidepressant medications (citalopram, duloxetine, fluoxetine, paroxetine, sertraline and venlafaxine). METHODS:Data wer...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560902849258

    authors: Kilts CD,Wade AG,Andersen HF,Schlaepfer TE

    更新日期:2009-04-01 00:00:00

  • Sibutramine: current status as an anti-obesity drug and its future perspectives.

    abstract:BACKGROUND:Obesity has become a global epidemic with recent estimates of > 400 million obese adults. Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2161

    authors: Sharma B,Henderson DC

    更新日期:2008-08-01 00:00:00

  • Current and emerging drug treatment strategies for peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1774556

    authors: Essa H,Torella F,Lip GYH

    更新日期:2020-09-01 00:00:00

  • Treatment of adult short bowel syndrome patients with teduglutide.

    abstract:INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.644787

    authors: Nørholk LM,Holst JJ,Jeppesen PB

    更新日期:2012-02-01 00:00:00

  • A pharmacoeconomic appraisal of therapies for hepatitis B and C.

    abstract::In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.2.205

    authors: Younossi ZM,Temple ME,Shermock KM

    更新日期:2001-02-01 00:00:00

  • Long-term oral carvedilol in chronic heart failure.

    abstract::The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF). Although the benefits observed with such drugs are viewed as a class effect, theoretically, carvedilol might ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.5.6.1359

    authors: Di Lenarda A,Sabbadini G,Moretti M,Sinagra G

    更新日期:2004-06-01 00:00:00

  • An economic commentary on the occurrence and control of HIV/AIDS in developing countries: special reference to India.

    abstract::HIV infection has a complex relationship with poverty, but affects both the rich and poor. HIV/AIDS represents the deadliest emergency and the greatest social, economic and health crisis of modern times. The HIV pandemic affects developed and developing countries differently, with up to 95% of new HIV infections now o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.7.18.2447

    authors: Muniyandi M,Ramachandran R,Balasubramanian R

    更新日期:2006-12-01 00:00:00

  • Safinamide in the treatment of Parkinson's disease.

    abstract:IMPORTANCE OF THE FIELD:Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.511612

    authors: Schapira AH

    更新日期:2010-09-01 00:00:00

  • Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults.

    abstract:BACKGROUND:Prescription omega-3-acid ethyl esters (P-OM3) have been used as adjunctive therapy to statin drugs in patients with mixed hyperlipidemia. OBJECTIVE:To assess the effect of concomitant administration of 4 g P-OM3 on the steady-state pharmacokinetics of the maximum recommended daily dose of atorvastatin (80 ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560802233827

    authors: Di Spirito M,Morelli G,Doyle RT,Johnson J,McKenney J

    更新日期:2008-12-01 00:00:00

  • Pharmacological treatment for uterine leiomyosarcomas.

    abstract:INTRODUCTION:Pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated. A thorough literature search was undertaken using the Pubmed databases. Systematic reviews and controlled trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.985205

    authors: Gadducci A,Guerrieri ME

    更新日期:2015-02-01 00:00:00